Folinic acid produced significant improvements in global ADOS score, social interaction, and communication, whereas placebo showed no meaningful change (Renard et al., 2020)
doi: 10.1093/advances/nmaa053
Unlike many neuropeptides that exert their effects primarily through binding to specific G-protein coupled receptors with well-characterized intracellular signaling cascades, DSIP appears to influence physiological processes through several complementary mechanisms
in vitro growth hormone secretion assays Cell lines Somatotroph cell cultures for mechanistic receptor studies Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite over two decades of preclinical investigation and limited early-phase human studies, the CJC-1295 (NO DAC) + Ipamorelin blend faces substantial evidence gaps that prevent clinical application: Lack of Human Clinical Data The most significant limitation is the absence of completed, peer-reviewed Phase III clinical trials: No FDA-approved indications for either peptide individually or in combination Phase II trials discontinued for CJC-1295 DAC following death of trial participant (though deemed unrelated by attending physician, development ceased as precautionary measure) Ipamorelin Phase II trials for postoperative ileus showed no significant efficacy versus placebo and were discontinued Long-term human safety profile completely unestablished beyond early-phase studies Optimal therapeutic dosing, treatment duration, and patient selection criteria unknown No published data on use in pediatric, geriatric, or medically complex populations Mechanistic Understanding Gaps Fundamental aspects of the peptide blends mechanisms require further elucidation: Disconnect between pharmacokinetics and pharmacodynamics peptides clear rapidly (hours) but effects persist for days
Here is the honest headline, stated up front
Oxidative stress induces skin pigmentation in melasma by inhibiting hedgehog signaling
